Patents by Inventor Valeria Szijárto

Valeria Szijárto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • specific antibodies
    Patent number: 12103962
    Abstract: The invention refers to an isolated antibody that specifically binds to O25b antigen of E. coli strains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in FIG. 1, and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in FIG. 1, or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 1, 2024
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Luis Guachalla, Maximiliano Vasquez
  • HIGH DOSE SHIGELLA VACCINE PREPARATION
    Publication number: 20230372462
    Abstract: A Shigella vaccine preparation comprising 10E8-10E12 CFU of a live, genetically attenuated Shigella flexneri strain that comprises a chromosomal deletion of setBA and which is non-invasive as determined by the Sereny test and an in vitro invasion assay using HeLa cells, wherein the strain comprises an endogenous invasion plasmid that is genetically engineered to incorporate a heterologous expression construct expressing a pathogen-specific antigen.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 23, 2023
    Applicant: EVELIQURE BIOTECHNOLOGIES GMBH
    Inventors: Eszter NAGY, Tamás HENICS, Petra GIRARDI, Irene NEUHAUSER, Shushan HARUTYUNYAN, Gábor NAGY, Valeria SZIJARTO
  • MDR E. COLI IMMUNOGEN
    Publication number: 20230277643
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Application
    Filed: November 22, 2022
    Publication date: September 7, 2023
    Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zóltan MAGYARICS, Irina MIRKINA, Luis GAUCHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
  • ANTIVIRAL USE OF CALIXARENES
    Publication number: 20230225988
    Abstract: A calixarene compound in an antiviral effective amount for use as an antiviral substance in a pharmaceutical preparation for use in prophylactic or therapeutic treatment of a disease condition which is caused by or associated with an infection with a virus.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 20, 2023
    Inventors: Eszter NAGY, Gabor NAGY, Valeria SZIJARTO, Robert KONRAT
  • ANTIBODIES TARGETING A GALACTAN-BASED O-ANTIGEN OF K. PNEUMONIAE
    Publication number: 20230220055
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Application
    Filed: August 16, 2022
    Publication date: July 13, 2023
    Applicant: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Valeria SZIJARTO, Gábor NAGY, Luis GUACHALLA, Zehra VISRAM, Eszter NAGY, Jolanta Katarzyna LUKASIEWICZ
  • AZELASTINE AS ANTIVIRAL TREATMENT
    Publication number: 20230201216
    Abstract: An Azelastine compound in an antiviral effective amount for use as an antiviral substance in a pharmaceutical preparation for use in prophylactic or therapeutic treatment of a subject in need of antiviral treatment.
    Type: Application
    Filed: May 28, 2021
    Publication date: June 29, 2023
    Inventors: Eszter NAGY, Gábor NAGY, Valeria SZIJARTO, Robert KONRAT
  • MDR immunogen
    Patent number: 11529405
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: December 20, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Eszter Nagy, Gäbor Nagy, Valéria Szijárto, Zóltan Magyarics, Irina Mirkina, Luis Gauchalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Antibodies targeting a galactan-based O-antigen of K. pneumoniae
    Patent number: 11466074
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: October 11, 2022
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Valeria Szijarto, Gábor Nagy, Luis Guachalla, Zehra Visram, Eszter Nagy, Jolanta Katarzyna Lukasiewicz
  • Antiviral treatment
    Patent number: 11433080
    Abstract: A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 ?g per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: September 6, 2022
    Assignee: CEBINA GMBH
    Inventors: Eszter Nagy, Gabor Nagy, Valeria Szijarto, Robert Konrat
  • ANTIVIRAL TREATMENT
    Publication number: 20220143040
    Abstract: A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 ?g per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.
    Type: Application
    Filed: December 27, 2021
    Publication date: May 12, 2022
    Inventors: Eszter NAGY, Gabor NAGY, Valeria SZIJARTO, Robert KONRAT
  • Antiviral treatment
    Patent number: 11273163
    Abstract: A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 ?g per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: March 15, 2022
    Assignee: CEBINA GMBH
    Inventors: Eszter Nagy, Gabor Nagy, Valeria Szijarto, Robert Konrat
  • ANTIVIRAL TREATMENT
    Publication number: 20210369730
    Abstract: A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 ?g per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 2, 2021
    Inventors: Eszter NAGY, Gabor NAGY, Valeria SZIJARTO, Robert KONRAT
  • MDR E. COLI SPECIFIC ANTIBODY
    Publication number: 20210162034
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Application
    Filed: February 4, 2021
    Publication date: June 3, 2021
    Applicant: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
  • MDR specific antibody
    Patent number: 10940191
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 9, 2021
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • KLEBSIELLA PNEUMONIAE O3 SPECIFIC ANTIBODIES
    Publication number: 20200339668
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 29, 2020
    Applicants: X4 Pharmaceuticals (Austria) GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Katharina RAMONI, Adriana BADARAU, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN, Irina MIRKINA
  • O3 specific antibodies
    Patent number: 10759848
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 1, 2020
    Assignees: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria Szijárto, Gábor Nagy, Luis Guachalla, Katharina Ramoni, Adriana Badarau, Eszter Nagy, Tim Rollenske, Hedda Wardemann, Irina Mirkina
  • ANTI-GALACTAN II MONOCLONAL ANTIBODIES TARGETING KLEBSIELLA PNEUMONIAE
    Publication number: 20190161534
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Application
    Filed: August 11, 2017
    Publication date: May 30, 2019
    Applicants: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN
  • KLEBSIELLA PNEUMONIAE O3 SPECIFIC ANTIBODIES
    Publication number: 20190153077
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Application
    Filed: August 11, 2017
    Publication date: May 23, 2019
    Applicants: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Katharina RAMONI, Adriana BADARAU, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN, Irina MIRKINA
  • MDR E. COLI SPECIFIC ANTIBODY
    Publication number: 20190111121
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 18, 2019
    Applicant: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
  • MDR specific antibody
    Patent number: 10206992
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 19, 2019
    Assignee: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz